April Braddy, PhD

Division Director, Division of Bioequivalence III, OB, OGD, CDER

Dr. April C. Braddy is the Director of the Division of Bioequivalence III in FDA’s Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research. She has been at the FDA since 2006 and has over 15 years’ experience as a regulator. Dr. Braddy began her career as a primary assessor and over the years have served in the roles of Team Leader, Associate Division Director and Deputy Division Director. She has led and co-chaired Center-level scientific committees and initiatives. In addition, Dr. Braddy has represented the Agency on multiple international global initiatives and is currently serving as the FDA’s liaison to the International Pharmaceutical Regulators Programme Bioequivalence Working Group for Generics. She is the author and contributor to over 10 publications which includes book chapters and peer-reviewed journal articles on bioequivalence standards, as well as numerous scientific posters and presentations at conferences during her FDA career. Dr. Braddy is an Excellence in Government Fellow and member of Rho Chi, an international honor society for pharmaceutical sciences. She earned a Ph.D. in Pharmaceutical Sciences (Pharmacy) from the University of Florida with a concentration in drug discovery – neuropharmacology and a B.Sc. in Microbiology with a minor in Chemistry from Clemson University.

Early bird tickets
available now